The United Nations Office at Geneva
Multimedia Newsroom
COVID-19: UN health agency issues conditional advice against using remdesivir
Patients with COVID-19 should not be given the antiviral drug remdesivir “regardless of disease severity”, the UN World Health Organization (WHO) said on Friday.
Nonetheless, describing its recommendation as “conditional”, as opposed to “strong”, WHO stressed that data from a global trial on the efficacy of remdesivir was inconclusive, and that further trials should continue into its use for more vulnerable patients.
“We recommend a conditional recommendation – I want to highlight that - against the use of remdesivir in hospitalised patients with COVID-19 regardless of disease severity,” said Dr Janet Diaz, Head of Clinical Care at WHO, during a virtual press conference in Geneva.
According to data from the WHO-led Solidarity trial which was then examined by a panel of international experts behind the recommendation, “possibly remdesivir can lead to 29 fewer deaths per 1,000 patients or up to 11 more deaths per 1000 patients”, Dr Diaz said. “So you can see that …the confidence interval are relatively large…there was no evidence that there was any important effect on mortality, on the need for mechanical ventilation or the time to clinical improvement.”
But this did “not prove” that the antiviral “had no benefit at all”, Dr Diaz insisted. “There could still be potential small benefit, maybe in a health sub-group which is why the panel also recommended continued trials, continued enrolment into clinical trials.”
The WHO official explained that this might be “severe patients versus critical patients” or whether the antiviral is used “early versus late”.
Dr Bram Rochwerg, who was among the experts advising WHO, noted that there would likely be regional “variations” in the use of remdesivir.
While a minority of people will still choose to use it, the majority would not, based on the available data, he said.
“There may be groups (who might benefit) and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit,” he said. “We were very explicit that we do believe that these studies need to continue (and) Solidarity is continuing.”
Although the remdesivir development mirrors similar attempts to use other antivirals against the new coronavirus, Dr Diaz said there was no reason to lose hope in the fight against COVID-19.
“I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”
Latest data from WHO indicates that eight in 10 people infected with COVID report mild symptoms, Dr Diaz said.
“Since the beginning (of the pandemic)…about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”
Nonetheless, there are reports of more “persistent longer-term symptoms”, Dr Diaz noted. “So even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We recommend a conditional recommendation - so I want to highlight that, it’s a conditional recommendation - against the use of remdesivir in hospitalized patients - with COVID-19, regardless of disease severity.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Possibly remdesivir can lead to 29 fewer deaths par 1,000 patients or up to 11 more deaths per 1,000 patients so you can see that this is, the confidence interval is a little bit large.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “It was not clear that, there was no evidence, that there was any important effect on mortality, on the need for mechanic ventilation or the time to clinical improvement.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “This did not prove that remdesivir does not have a benefit at all and that’s why it is a conditional recommendation, there can still be potential small benefit, maybe in a health sub-group, which is why the panel also recommended continued trials, continued enrolment into clinical trials.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “You know, is there a sub-group that may benefit more – such as severe patients versus critical patients. Is there a timing in disease that may benefit more - such as early versus late - and those are all considerations that are in the guidelines.”
- SOUNDBITE (English) — Dr Bram Rochwerg, practising ITU clinician and expert adviser for WHO-led Solidarity Trial: “There may be groups and the data was a bit more of a close call, so that’s why we felt strongly that trials need to continue using remdesivir and studying remdesivir and looking to see if there are specific groups that might, that might benefit. And as she said, we were very explicit that we do believe that these studies need to continue, Solidarity is continuing, so.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “I do think there is a tremendous global effort to investigate treatments. You know, I think a lot of interest was done upfront with the repurposed of drugs, repurposed antivirals, you know we saw that with other repurposed drugs such as hydroxychloroquine, lopinavir, and there was a big push to try to test these and they’ve been tested and unfortunately, we just haven’t, you know, the results haven’t been as promising as we had hoped. But I don’t want to, I don’t want to forget that we do have one lifesaving drug and even though it’s a repurposed old, old drug dexamethasone, a corticosteroid, we do know that that does reduce mortality, save lives of patient with severe and critical so there is something.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “Since the beginning, is that about 80 per cent of people have, you know, mild disease, a proportion maybe moderate disease and then only a small proportion, a smaller proportion, 20 per cent go on to develop severe or critical disease, and critical disease is a small, small portion, it’s five per cent or less, and that is…and that seems to be kind of consistent I think through the literature so most patients do have, if they have mild disease, self-limiting disease, they get better on their own, their immune system kicks in and they get better.”
- SOUNDBITE (English) — Dr Janet Diaz, Head of Clinical Care, WHO: “We do know that even patients with mild disease may have persistent longer-term symptoms. And that has been now described; so even though they don’t get severe disease there can be some persistent symptoms that lasts longer than one would have hoped for.”
Similar Stories
1
1
1
Edited News | OHCHR , UNOG
UN Human Rights Chief Volker Türk has called on the Georgian authorities to respect and protect the rights to freedoms of expression and peaceful assembly following several nights of protests that were marred by violence, and dispersed using disproportionate, and in some cases unnecessary, force by the police in the capital, Tbilisi.
1
1
1
Edited News | OHCHR , UNOG
UN High Commissioner for Human Rights Volker Türk said today he was extremely concerned about the recent escalation in hostilities in northwest Syria, which further compounds the suffering endured by millions of civilians.
1
1
1
Edited News | OHCHR , WHO , OCHA
Syria escalation: Civilians face deadly attacks, health care in distress and aid access compromised
The ongoing escalation of violence in northwest Syria linked to the wider conflict in Gaza and Lebanon has left civilians dead and injured, hospitals “overwhelmed” and attacks on healthcare on the rise, the UN warned on Tuesday.
2
1
4
Press Conferences , Edited News | OCHA
Multiple unending conflicts, climate change and a glaring disregard for long-established international humanitarian law are set to leave a staggering 305 million people in need of lifesaving assistance next year, the UN’s top aid official warned on Wednesday.
Embargo Wednesday, 4 December 2024 at 0600 CET / 0000 ET
1
1
1
Edited News | OHCHR , UNOG
The UN Rights Office on Friday warned about the plight of civilians in Ukraine after further attacks on the country’s energy infrastructure.
1
1
1
Edited News | ITU
An international panel has been set up to protect undersea communications cables that are crucial for international trade and security, the UN International Telecommunication Union (ITU) said on Friday. The creation of the International Advisory Body for Submarine Cable Resilience comes amid an ongoing investigation into the severing of two fibre optic cables in the Baltic Sea, in less than 24 hours between 17 and 18 November.
2
1
2
Press Conferences , Edited News | ITU
An estimated 5.5 billion people have access to the internet in 2024, an increase of 227 million people based on revised estimates for 2023, the UN specialized agency for telecommunications, ITU, said on Wednesday.
2
1
2
Press Conferences , Edited News | UNAIDS
Launch of World AIDS Day Report 2024—Take The Rights Path
1
1
1
Edited News | OHCHR , UNOG
A joint report issued this morning by the UN Human Rights Office and the UN Assistance Mission in Afghanistan (UNAMA) paints a disturbing picture of the media landscape in the country since the Taliban takeover. UN Human Rights Chief Volker Türk says.
1
1
1
Edited News | OHCHR
UN human rights chief Volker Türk lent his weight to growing ceasefire calls in Lebanon on Tuesday, amid reports that the senior Israeli cabinet members were due to meet on a deal to end more than a year of conflict with Hezbollah militants, sparked by the war in Gaza
1
1
1
Edited News | OCHA , UNHCR , WHO
The past two months of intensifying Israeli bombardment in Lebanon have been the “deadliest and most devastating” in decades as communities uprooted from the front line have continued to flee across the border to Syria, UN humanitarians said on Friday.
2
1
3
Edited News | UNOG
“State of Silence”: Diego Luna brings the fight to protect the press to the UN in Geneva
Mexican actor, producer and director Diego Luna has brought his fight to protect journalists all the way to the United Nations, in Geneva. Together with documentary director Santiago Masa, he is putting a spotlight on the silencing of investigative journalism in his country, and on the incredibly high price that many journalist have to pay in pursuit of truth.